We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGS icon
51
Aligos Therapeutics
ALGS
$25.9M
$36.6M 0.16%
64,400
– –
AXSM icon
52
Axsome Therapeutics
AXSM
$11.7B
$35.6M 0.15%
628,414
-150,420
-19% -$10.6M
ADCT icon
53
ADC Therapeutics
ADCT
$139M
$34.6M 0.15%
1,418,107
– –
CCXI
54
DELISTED
ChemoCentryx, Inc.
CCXI
$33.6M 0.15%
656,710
– –
OPT
55
DELISTED
Opthea Limited American Depositary Shares
OPT
$31.7M 0.14%
3,308,705
– –
SYRE icon
56
Spyre Therapeutics
SYRE
$8.28B
$27M 0.12%
136,404
– –
NVAX icon
57
Novavax
NVAX
$1.2B
$26.1M 0.11%
143,756
-25,950
-15% -$5.17M
ALKS icon
58
Alkermes
ALKS
$8.1B
$22.9M 0.1%
1,228,170
-306,979
-20% -$6.28M
MREO
59
Mereo BioPharma
MREO
$50M
$22.6M 0.1%
6,719,948
+689,655
+11% +$2.44M
RETA
60
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$22.3M 0.1%
223,976
– –
OTIC
61
DELISTED
Otonomy, Inc.
OTIC
$18.4M 0.08%
+7,220,074
New +$29.6M
AUPH icon
62
Aurinia Pharmaceuticals
AUPH
$1.92B
$18.3M 0.08%
1,410,064
– –
EWTX icon
63
Edgewise Therapeutics
EWTX
$4.21B
$16.3M 0.07%
+500,000
New +$16.2M
XNCR icon
64
Xencor
XNCR
$1.44B
$15.9M 0.07%
369,370
– –
LONA
65
LeonaBio Inc
LONA
$63.4M
$14.8M 0.06%
80,637
– –
ALBO
66
DELISTED
Albireo Pharma Inc
ALBO
$14.5M 0.06%
412,466
– –
XENE icon
67
Xenon Pharmaceuticals
XENE
$6.16B
$13.5M 0.06%
751,639
+64,253
+9% +$1.09M
MIRM icon
68
Mirum Pharmaceuticals
MIRM
$6.56B
$12.8M 0.06%
647,313
– –
KDNY
69
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.6M 0.05%
748,693
– –
SPRY icon
70
ARS Pharmaceuticals
SPRY
$550M
$10.4M 0.05%
238,095
– –
RVMD icon
71
Revolution Medicines
RVMD
$38B
$10.2M 0.04%
+222,222
New +$9.97M
CBAY
72
DELISTED
Cymabay Therapeutics
CBAY
$9.85M 0.04%
2,170,464
-722,812
-25% -$3.89M
GTH
73
DELISTED
Genetron Holdings Limited ADS
GTH
$9.77M 0.04%
151,769
– –
HOOK
74
DELISTED
HOOKIPA Pharma
HOOK
$9.42M 0.04%
70,048
– –
CRNX icon
75
Crinetics Pharmaceuticals
CRNX
$8.88B
$9.42M 0.04%
616,520
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.